Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer - Wikidata - wikimedia - TriplyDB

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

http://www.wikidata.org/entity/Q42000250

about

Tumor angiogenesis: pericytes and maturation are not to be ignored Biomarkers of Angiogenesis in Colorectal Cancer Targeting triple-negative breast cancer: optimising therapeutic outcomes Recent applications of chemosensitivity tests for colorectal cancer treatment Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Anti-vascular endothelial growth factor therapy in breast cancer VEGF targets the tumour cell.The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Onco Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo.Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer.Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Randomized phase II trial designs with biomarkers.Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.Bevacizumab and breast cancer: what does the future hold?A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions Clinical implications of DLL4 expression in gastric cancer Controlling escape from angiogenesis inhibitors.Targeting notch signaling pathway in cancer: clinical development advances and challenges First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.Zebrafish phenotypic screen identifies novel Notch antagonists.Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.Antiangiogenic therapy in breast cancer.Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.

P2860

Q21296683-A7AA3CF0-7DF5-483F-91B6-A705FD413931 Q26778891-101EFACE-B664-46E4-9480-F79707FC4D48 Q26850892-C389E83B-944C-4219-A6E5-CEE8381ACCA6 Q26851075-388FCDC8-CB02-4FA6-8F7F-A029B87BC1A9 Q26996793-6FA4EF05-9822-4B1B-9B52-D62DD2BDFBFE Q26999473-B7623627-3FF4-4C74-8817-531C813D3BE0 Q33573324-93EBA951-AEBA-41F0-B20C-D68CD34E738C Q33739381-E7089781-28BA-4E19-B81E-E4012C3723F1 Q34916073-58CDC798-B224-4243-8FD5-B6D37A885BF6 Q34975326-1C7EC745-3FEA-4654-A675-8C95A5DF9EA5 Q35172301-D70396BD-712E-4CC6-BDB8-D00CDDE6B051 Q35216301-AD603419-48FD-47EF-BEA2-D79E4984ED4D Q35418092-0A56AB4F-1A03-45FD-A1A8-CD542B43EB4D Q35536088-C3108487-5929-4434-824C-D065BD2C5C30 Q36182824-527448D7-BBF0-4D53-8CB6-57E0649D35B3 Q36212448-0C9DE6F4-3586-4957-9891-E75943EBC5AA Q36286704-79CBB93B-1EB3-4F5F-BBB0-1B8F1B8F25B2 Q36298210-6A207D06-F94C-4CE9-8C8B-A7FCB4511299 Q36333585-179EDBCB-1B91-49F7-9034-09ABD5CA23A8 Q36700844-9E2FE08A-E4FD-4A54-AF13-F8D180056CC3 Q36746794-F0D86D2D-A5DB-48C4-8314-AA7549E258F2 Q36828220-A59431D7-F235-4125-8EEC-46CAF565EBE8 Q36901312-EAEB6A69-95BB-447F-A22C-D59592C4E539 Q37114635-E520814C-8C2E-4781-987F-580865CFDD7D Q37672654-EF18C02D-0F94-4AEF-98E6-AD7CF3239701 Q37696748-86DFC704-0217-444B-BD49-3926CA4D5CCB Q37909171-5A1EEDB8-CCA4-4343-9097-EFE5E3D74CE1 Q37950522-387FFCF3-E9FA-4848-A69B-F900CE3FDF5A Q37958937-FF932AD8-3EC0-4E09-B394-E189FBCCB7FE Q37969851-2D0CE667-7F50-4A27-9265-C46963047030 Q38020234-7FE8B46C-9D39-4475-BF5D-89A1A1AE5BF2 Q38075848-92E0EBC6-333B-4572-B333-64B353659480 Q38188598-786AF067-E2BE-4BDC-A0CE-FCC13230F2FC Q39036896-DCFDB679-D452-4EA8-AD29-ADF9256893C0 Q39521987-FD4BE45F-B1CC-478A-8B1E-2F7004F3D2E0 Q39609867-B96D6BF2-8E68-4C90-BE01-5A5128C453E8 Q41892380-145ED5DF-26E6-494B-9C93-C1FAFF451254 Q42481201-98BA451B-531E-47EB-A965-042209233FFD Q47111400-2D462134-60E5-4567-84BF-0C98E5A4DA2B Q47228068-CF8C63F9-F053-4CE9-BF5F-B8808911A5C1

P2860

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

http://www.wikidata.org/entity/Q42000250

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@en

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@nl

type

label

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@en

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@nl

prefLabel

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@en

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@nl

P1433

Q42000250-65767900-74EC-40F0-A9E4-67AC4B2D77E9

P1476

Q42000250-BA3A2034-10E9-4AD8-A01E-5355D7091F9C

P2093

Q42000250-18434586-788F-4D7A-A599-91AE7432DF72

Q42000250-53FE9E13-1C1C-4D20-9DDC-32BCEB77E452

Q42000250-54CFEDC8-AF30-419E-893B-CA8F4CB89B52

Q42000250-9B0BC797-24D7-445F-9B86-79A9199D8D07

Q42000250-9D80F4EC-C525-4C3F-B520-5D30B3EE40D8

Q42000250-A6874EFB-E042-4E24-BC4B-5B31D2411D9C

Q42000250-AC3D6CD4-635E-4391-9E60-876D7A7F062E

Q42000250-B706004A-E837-40CB-B38B-85B7EF80B7D2

Q42000250-BE4A1A88-FDA4-4D77-BDB9-1D5005B4F3B3

Q42000250-F1896136-5489-49E9-88BB-3891D4448B4C

P2860

Q42000250-099B5FB1-C649-47F7-A3DB-3669BDFD508B

Q42000250-108DAF75-238D-40A7-998B-DC50A962BD87

Q42000250-1AC24A8F-C183-495C-96B5-872097423F8C

Q42000250-1E1A550A-D65F-46EE-9321-C8EADC90EC28

Q42000250-212A8548-44B4-4532-BC90-0AD886825154

Q42000250-23F5344E-AAD8-4D74-83DD-94F0A8C016C5

Q42000250-259D7245-FB1C-4FDB-A8A0-D3F531D4E79E

Q42000250-27122E3E-432C-4504-80BE-4E6E458EBA87

Q42000250-271FA62E-CC24-4BF1-A9C2-4635084B4931

Q42000250-2B67C7F5-557F-490C-8306-F95A3D7BFF4B

P304

Q42000250-361CBBDE-2C41-46EB-BE7C-2B7ECA53AF61

P31

Q42000250-34E7ED67-B1CE-4F2B-980F-EC4E47A8572A

P356

Q42000250-BBDB3999-80DA-496E-AFD8-04A0182A89D8

P407

Q42000250-73454332-6F5C-45E4-BB0A-0C6C478E4339

P433

Q42000250-ECB0354B-7DE0-427A-B2A4-02C3B21C3E34

P478

Q42000250-61F691F2-8881-4668-AF64-BDE1FF3B22DF

P50

Q42000250-6BD1C2C0-F630-4648-897F-0333B6EB2052

P577

Q42000250-E60C0D54-38EB-4CB0-BF30-C6C25F94A670

P698

Q42000250-9E1F4916-6FC2-4B6E-A65B-3E75565541E3

P921

Q42000250-B4DFFFD6-BBB1-4157-8B1C-806A164CD284

Q42000250-F3176BD1-DAEC-4007-9E42-FEBF64758C24

P932

Q42000250-0C81B06C-4B4E-49EA-B691-64E2C3DB6D93

P356

1078-0432.CCR-10-1791

P1433

Clinical Cancer Research

P1476

Impact of exploratory biomarke ...... ab in metastatic breast cancer

@en

P2093

Adrian M Jubb

http://www.w3.org/2001/XMLSchema#string

Dafeng Chen

http://www.w3.org/2001/XMLSchema#string

Daniel S Chen

http://www.w3.org/2001/XMLSchema#string

Hartmut Koeppen

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

James D Reimann

http://www.w3.org/2001/XMLSchema#string

Kathy D Miller

http://www.w3.org/2001/XMLSchema#string

Kenneth J Hillan

http://www.w3.org/2001/XMLSchema#string

Maike Schmidt

http://www.w3.org/2001/XMLSchema#string

Melody A Cobleigh

http://www.w3.org/2001/XMLSchema#string

P2860

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

P304

372-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-1791

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

P577

2011-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21224365

http://www.w3.org/2001/XMLSchema#string

P921

P932

3023787

http://www.w3.org/2001/XMLSchema#string